1. Introduction

The Corporate Genome Doctrine is a proposed interdisciplinary legal and governance framework that examines how genetic information, genomic technologies, biotechnology, and biological data intersect with corporate identity, corporate responsibility, organizational decision-making, and legal accountability.

The concept extends beyond conventional corporate governance. It examines the legal consequences arising when corporations collect, analyse, store, commercialize, modify, or utilize human genetic information and genomic technologies.

The doctrine raises a fundamental question:

To what extent should a corporation be legally responsible for the acquisition, processing, commercialization, protection, and misuse of genetic and genomic information?

It connects corporate law with constitutional law, biotechnology regulation, intellectual property, privacy, medical ethics, data protection, consumer protection, and human rights.

An important qualification is that Corporate Genome Doctrine is not presently a universally recognized, independently codified legal doctrine. It is an analytical framework that can be developed from established legal principles and judicial precedents.

2. Meaning and Scope of the Corporate Genome Doctrine

The doctrine can be understood through five interconnected dimensions:

Corporate genomic identity: How corporations develop policies, institutional structures, and commercial strategies involving genetic technologies.

Genomic data responsibility: Corporate obligations concerning the collection, processing, storage, and disclosure of genetic information.

Genetic discrimination: Prohibition of unfair treatment based on genetic characteristics or predicted biological conditions.

Biotechnology accountability: Liability arising from corporate research, genetic modification, genetic testing, and commercialization.

Genomic sovereignty: Protection of individual autonomy and control over personal genetic information against unauthorized corporate exploitation.

The central proposition is that genetic information must not become an unrestricted commercial asset merely because a corporation possesses the technological capacity to process it.

3. Major Legal Principles of the Doctrine

A. Corporate Genomic Privacy and Data Protection

Corporations involved in genetic testing, pharmaceutical research, biotechnology, healthcare platforms, and genomic databases may obtain highly sensitive personal information.

Such information can reveal:

Hereditary diseases and genetic predispositions.

Family relationships and biological ancestry.

Reproductive characteristics.

Potential health risks.

Biological relationships between individuals.

Information about family members who have never directly consented to data collection.

The doctrine therefore proposes that corporations should observe strict standards of purpose limitation, informed consent, confidentiality, data minimization, security, and responsible retention.

Indian legal framework

The principal constitutional foundation is Article 21 of the Constitution of India, which protects life, personal liberty, dignity, and privacy.

The Digital Personal Data Protection Act, 2023, provides a statutory framework for processing digital personal data. Its application to genomic information depends on whether the information qualifies as digital personal data and on the applicable statutory provisions and rules.

B. Corporate Ownership and Commercialization of Genetic Material

A fundamental question is whether corporations can claim proprietary rights over human genetic material or information simply because they discover, isolate, sequence, or commercially exploit it.

The doctrine distinguishes between:

Naturally occurring genetic material.

Human biological samples.

Genomic information.

Synthetic genetic constructs.

Patentable biotechnology inventions.

Commercial applications developed using genomic research.

The distinction is important because discovery of something naturally occurring is not necessarily equivalent to creating a patentable invention.

C. Corporate Genetic Discrimination

The doctrine proposes restrictions on corporate decisions based on genetic characteristics.

Potentially problematic practices include:

Employers rejecting candidates based on genetic predispositions.

Insurance businesses using genetic information unfairly.

Companies creating discriminatory consumer classifications.

Corporations using genomic information without meaningful consent.

Commercial profiling based on hereditary characteristics.

The underlying legal principles include equality, privacy, dignity, non-discrimination, and consumer protection.

D. Corporate Fiduciary and Ethical Responsibilities

Corporations conducting genomic research should be subject to rigorous ethical governance.

The proposed responsibilities include:

Transparent research protocols.

Independent ethical review.

Informed consent.

Disclosure of commercial interests.

Protection of research participants.

Responsible commercialization.

Prevention of unauthorized secondary use.

The doctrine treats corporate access to human biological information as a source of legal responsibility rather than an unrestricted commercial privilege.

E. Corporate Biotechnology Liability

A corporation may face legal consequences where its genomic activities cause injury or violate applicable law.

Possible liability categories include:

The existence and extent of liability depend on the applicable legislation, the corporation's conduct, causation, and available legal remedies.

4. Important Judicial Decisions and Case Laws

The following decisions provide the principal judicial foundations for developing the Corporate Genome Doctrine.

1. Moore v. Regents of the University of California (1990)

Citation: 51 Cal. 3d 120; 793 P.2d 479.

Court: Supreme Court of California.

Facts: John Moore's cells were used in valuable medical research without adequate disclosure of the researcher's economic interests. A commercially valuable cell line was subsequently developed.

Judgment: The Court recognized that the allegations could support claims based on breach of fiduciary duty and lack of informed consent. However, it rejected Moore's conversion claim concerning the excised cells.

Relevance to Corporate Genome Doctrine:

Commercial research using human biological material raises informed-consent obligations.

Researchers must disclose relevant financial interests.

Commercial exploitation does not eliminate ethical duties.

Corporate biotechnology arrangements may create conflicts of interest.

This is particularly important for corporate genomic research and commercialization.

Justia Law+1

2. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Citation: 569 U.S. 576.

Court: Supreme Court of the United States.

Facts: Myriad Genetics identified the BRCA1 and BRCA2 gene sequences and obtained patents relating to them.

Judgment: The Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated. However, synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the applicable patent requirements.

Relevance:

Corporations cannot claim patent monopolies over naturally occurring human DNA merely through discovery and isolation.

Biotechnology innovation must be distinguished from discovery of natural phenomena.

Genomic commercialization must respect the boundaries of patent law.

Human genetic information raises questions beyond ordinary commercial ownership.

This judgment establishes an important limitation on corporate control over naturally occurring genetic material.

LII / Legal Information Institute+1

3. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1.

Court: Supreme Court of India, nine-judge Constitution Bench.

Facts: The case concerned whether privacy is constitutionally protected, particularly in the context of governmental collection and use of personal information.

Judgment: The Supreme Court unanimously recognized privacy as a fundamental right under the Constitution, primarily protected through Article 21 and the freedoms guaranteed by Part III.

The judgment recognized informational privacy, individual autonomy, dignity, and the need for lawful and proportionate restrictions.

Relevance:

Genetic information can fall within the sphere of informational privacy.

Corporate handling of genomic data raises questions of individual autonomy.

Unauthorized disclosure may implicate privacy and dignity.

The State has positive obligations to protect privacy through appropriate legal frameworks.

The judgment is a significant constitutional foundation for genomic data governance in India.

Indian Kanoon+1

4. S. and Marper v. United Kingdom (2008)

Citation: Applications Nos. 30562/04 and 30566/04.

Court: European Court of Human Rights, Grand Chamber.

Facts: The UK authorities retained fingerprints, cellular samples, and DNA profiles of individuals who had been arrested but subsequently acquitted or had proceedings discontinued.

Judgment: The Court found a violation of Article 8 of the European Convention on Human Rights. Indefinite and indiscriminate retention of such personal information was disproportionate.

Relevance:

DNA samples contain exceptionally sensitive personal information.

Genetic information can reveal relationships between family members.

Retention itself can interfere with privacy.

Storage and processing require adequate legal safeguards.

Corporate application: Corporations maintaining genomic databases should establish retention limits, access restrictions, deletion procedures, and safeguards against unauthorized secondary use.

bailii.org+1

5. Diamond v. Chakrabarty (1980)

Citation: 447 U.S. 303.

Court: Supreme Court of the United States.

Facts: An inventor developed a genetically engineered bacterium capable of breaking down multiple components of crude oil.

Judgment: The Court held that the human-made genetically modified microorganism was patentable subject matter under the applicable US patent legislation.

Relevance:

Human-created biotechnology may qualify for intellectual property protection.

Natural biological phenomena and engineered biological inventions must be distinguished.

Biotechnology companies can obtain commercial rights over qualifying inventions.

Patent rights remain subject to statutory limitations.

This judgment complements Myriad Genetics: engineered biological inventions and naturally occurring human genes are not legally identical categories.

LII / Legal Information Institute+1

5. Indian Legislative Framework

The Corporate Genome Doctrine can be developed through several Indian legislative frameworks.

Particular importance of the Patents Act, 1970

Section 3(c) excludes the mere discovery of a scientific principle or formulation of an abstract theory and the discovery of a living thing or non-living substance occurring in nature from patentability.

Section 3(j) excludes plants and animals in whole or any part thereof, other than microorganisms, as well as essentially biological processes for production or propagation of plants and animals.

This provision is particularly important for corporations involved in genetic engineering, biotechnology, and genomic product development.

6. Corporate Governance Obligations Under the Doctrine

The proposed doctrine would establish a specialized governance framework for corporations working with genetic information.

7. Corporate Genome Doctrine and Directors' Duties

An important extension of this doctrine concerns the responsibility of directors.

Under Section 166 of the Companies Act, 2013, directors have statutory duties concerning good faith, the interests of the company, its employees, shareholders, the community, and environmental protection.

For biotechnology corporations, these duties can be examined in relation to:

Preventing unlawful exploitation of genomic information.

Ensuring appropriate research oversight.

Supervising compliance with privacy legislation.

Preventing conflicts of interest in genetic research.

Establishing effective internal accountability systems.

Ensuring that corporate profitability does not override applicable legal and ethical obligations.

The doctrine would therefore support the development of genomic risk oversight as part of modern corporate governance.

8. Corporate Genome Doctrine and Human Rights

The doctrine has important implications for human rights.

Right to privacy: Individuals should have protection against unauthorized genomic surveillance.

Right to dignity: Human genetic characteristics should not become instruments of humiliation, exploitation, or commercial manipulation.

Right to equality: Genetic predispositions should not automatically determine employment, commercial, or social opportunities.

Right to bodily autonomy: Individuals should retain meaningful control over participation in genetic research and collection of biological samples.

Right to informed consent: Genetic testing and research should be supported by legally adequate consent procedures.

Right to benefit-sharing: Where applicable, biological-resource access and benefit-sharing legislation should be respected.

9. Corporate Genome Doctrine: Emerging Legal Challenges

FUTURE LEGAL DEVELOPMENT

The doctrine raises several questions that conventional corporate law has not comprehensively resolved.

A. Genetic data ownership

Can a corporation claim ownership over genomic information generated from an individual's biological sample?

B. Hereditary privacy

If a genetic database reveals information about an individual's relatives, what duties does the corporation owe to those relatives?

C. Artificial intelligence and genomic prediction

Should corporations be liable for discriminatory decisions made through AI systems trained on genetic datasets?

D. Corporate genetic surveillance

What legal restrictions should apply when corporations collect genetic information for purposes beyond those originally disclosed?

E. Genetic modification liability

Who should bear responsibility when corporate genetic engineering produces unintended biological or environmental consequences?

F. Intergenerational responsibility

Can corporate genomic activities create legal responsibilities concerning risks to future generations?

These questions require the integration of corporate governance, constitutional protections, biotechnology regulation, and emerging data-protection principles.

10. Proposed Seven Principles of the Corporate Genome Doctrine

The doctrine can be systematically formulated through seven principles:

1. Principle of Genetic Autonomy: Individuals retain autonomy over participation in genomic research and testing.

2. Principle of Genomic Privacy: Genetic information requires stringent confidentiality and security safeguards.

3. Principle of Non-Commercial Appropriation: Corporations cannot assume unrestricted proprietary rights over naturally occurring human genetic material.

4. Principle of Informed Commercialization: Commercial use of biological samples and associated information must respect applicable consent and disclosure requirements.

5. Principle of Genetic Non-Discrimination: Genetic characteristics should not be used for unlawful or unjustified discriminatory treatment.

6. Principle of Corporate Accountability: Corporate entities must remain accountable for unlawful genomic data processing, research misconduct, and other legally actionable violations.

7. Principle of Intergenerational Protection: Genomic research should consider potential consequences for relatives, future generations, and the environment.

11. Critical Analysis

The Corporate Genome Doctrine presents a significant conceptual development in the relationship between corporate power and biological information.

Traditional corporate governance primarily concerns capital, shareholders, management, contractual obligations, and commercial risk. Biotechnology corporations introduce a different category of risk because their activities may affect biological identity, hereditary information, medical autonomy, and human dignity.

Three major tensions emerge.

First, innovation versus individual rights: Excessively restrictive rules may obstruct legitimate medical research, while insufficient safeguards may enable exploitation of genetic information.

Second, intellectual property versus public interest: Commercial incentives can encourage biotechnology innovation, but patent protection must not improperly extend to naturally occurring human genetic material.

Third, corporate efficiency versus accountability: Automated genomic analysis can improve medical research, but corporations must not evade responsibility by attributing harmful decisions exclusively to algorithms.

The appropriate legal response is not to prohibit genomic commercialization. It is to establish clear boundaries between legitimate innovation and unlawful exploitation.

12. Conclusion

The Corporate Genome Doctrine can be understood as a proposed framework for regulating corporate power over genetic information, biological materials, genomic technologies, and biotechnology commercialization.

Its judicial foundation can be developed through the combined principles of:

Moore v. Regents — informed consent and commercial exploitation of human biological material.

Myriad Genetics — limitations on patent claims over naturally occurring human DNA.

Puttaswamy — informational privacy, dignity, and individual autonomy.

S. and Marper — genetic privacy and proportionate retention of DNA information.

Diamond v. Chakrabarty — patent protection for qualifying human-engineered biological inventions.

The central legal proposition is that corporate access to the human genome must generate corresponding legal responsibilities. Scientific innovation, corporate profitability, and intellectual property protection must operate within the boundaries of human dignity, privacy, autonomy, equality, and applicable law.

The doctrine thus provides a foundation for a future branch of corporate jurisprudence that may be described as Corporate Genomic Governance and Accountability Law.

13. Selected Primary Legal Sources

Puttaswamy v. Union of India (2017).

Myriad Genetics (2013).

Moore v. Regents (1990).

S. and Marper v. United Kingdom (2008).

Diamond v. Chakrabarty (1980).

Academic qualification: These judgments establish separate legal principles. They should not be cited as having expressly recognized or applied a unified Corporate Genome Doctrine.